Latest news articles

Added 4 days ago Drug news

Phase III MAP US study of RHB 104 meets endpoint in Crohn’s disease.-RedHill Biopharma

RedHill Biopharma announced full Week 52 results for all subjects in the previously announced positive Phase III randomized, controlled study...

Added 1 month ago Drug news

European Union approves Stelara for moderately to severely active ulcerative colitis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved the expanded use of...

Added 2 months ago Drug news

FDA approves Hadlima an adalimumab biosimilar

Samsung Bioepis Co., Ltd. announced that the FDA has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) , for the...

Search all news articles for Regional enteritis and ulcerative colitis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Anti-integrins in IBD

Anti-integrins in IBD

See presentations from a satellite symposium presented at UEG Week 2018, with a particular focus on rapid and sustained efficacy in IBD through biologics along with a need to utilise patient-empowered treatment models.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Load more

Guidelines

Ulcerative colitis: management

This guideline covers the management of ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support...

Added 2 months ago

Crohn's disease: management

Crohn's disease is a chronic inflammatory disease that mainly affects the gastrointestinal tract. The disease may be progressive in some people, and a proportion may develop extra-intestinal manifestations.

Added 7 years ago

Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition

Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea...

Added 1 year ago

Search all guidelines for Regional enteritis and ulcerative colitis
 

Journal articles

Faecal microbiota transplantation: a regulatory hurdle?

During faecal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysbiosis-associated gut diseases. Competent authorities are faced with the challenge to provide adequate regulation.

Added 5 months ago

A knowledgebase resource for interleukin-17 family mediated signaling.

Interleukin-17 (IL-17) belongs to a relatively new family of cytokines that has garnered attention as the signature cytokine of Th17 cells. This cytokine family consists of 6 ligands, which bind to 5 receptor subtypes and induce...

Added 6 months ago

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge.

Added 6 months ago

Search all journal articles for Regional enteritis and ulcerative colitis
 

Clinical trials

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in...

Added 1 year ago

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor...

Added 1 year ago

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

The primary objective of this study is to investigate the mechanisms that underlie primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADRs) to anti-TNF drugs in patients with active luminal Crohn's disease.

Added 1 year ago

Search all clinical trials for Regional enteritis and ulcerative colitis
 
Allen Wellings

UEGW 2018 | Day 5 Highlights

A number of presentations and abstracts shared updates on the latest developments for new treatments and therapies, some of which are pioneering new modes of action. Here we look to the horizon, gaining insights into the latest data for novel treatments targeting Janus kinase (JAK) signalling, MAdCAM-1-mediated adhesion and the interleukin IL-23.